Items Tagged ‘stage III’

May 7, 2018

FDA Approves Tafinlar® + Mekinist® for Adjuvant Treatment of BRAF V600-mutant Stage III Melanoma

By

CancerConnect News: The US Food and Drug Administration (FDA) has approved Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for the adjuvant treatment of patients with stage III melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.1 About Melanoma  Stage III melanoma includes cancers of any thickness that have spread to the […]

View full entry

Tags: adjuvant treatment, BRAF V600E, dabrafenib, mekinist, Melanoma, News, precision cancer medicines, stage III, tafinlar, trametinib, V600K mutations


October 17, 2017

Imfinzi Improves Survival in Stage 3 Non Small Cell Lung Cancer

By

Immunotherapy could be the new standard of care in patients with non-small cell lung cancer (NSCLC).  The novel immunotherapy checkpoint inhibitors Keytruda® (pembrolizumab) and Opdivo (nivolumab) are already standard of care for advanced NSCLC.1   A recently published study has demonstrated that patients with earlier stage III, locally advanced NSCLC may benefit from anther checkpoint inhibitor Imfinzi […]

View full entry

Tags: checkpoint inhibitor, durvalumab, Imfinzi, immunotherapy, keytruda, locally advanced NSCLC, Lung Cancer, News, nivolumab, opdivo, pembrolizumab, Precision Cancer Medicine